Ulcerative Colitis Induces Changes on the Expression of the Endocannabinoid System in the Human Colonic Tissue

Background Recent studies suggest potential roles of the endocannabinoid system in gastrointestinal inflammation. Although cannabinoid CB2 receptor expression is increased in inflammatory disorders, the presence and function of the remaining proteins of the endocannabinoid system in the colonic tissue is not well characterized. Methodology Cannabinoid CB1 and CB2 receptors, the enzymes for endocannabinoid biosynthesis DAGLα, DAGLβ and NAPE-PLD, and the endocannabinoid-degradating enzymes FAAH and MAGL were analysed in both acute untreated active ulcerative pancolitis and treated quiescent patients in comparison with healthy human colonic tissue by immunocytochemistry. Analyses were carried out according to clinical criteria, taking into account the severity at onset and treatment received. Principal Findings Western blot and immunocytochemistry indicated that the endocannabinoid system is present in the colonic tissue, but it shows a differential distribution in epithelium, lamina propria, smooth muscle and enteric plexi. Quantification of epithelial immunoreactivity showed an increase of CB2 receptor, DAGLα and MAGL expression, mainly in mild and moderate pancolitis patients. In contrast, NAPE-PLD expression decreased in moderate and severe pancolitis patients. During quiescent pancolitis, CB1, CB2 and DAGLα expression dropped, while NAPE-PLD expression rose, mainly in patients treated with 5-ASA or 5-ASA+corticosteroids. The number of immune cells containing MAGL and FAAH in the lamina propria increased in acute pancolitis patients, but dropped after treatment. Conclusions Endocannabinoids signaling pathway, through CB2 receptor, may reduce colitis-associated inflammation suggesting a potential drugable target for the treatment of inflammatory bowel diseases.

[1]  Stephen P. H. Alexander,et al.  Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[2]  K. Mackie,et al.  Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei , 2008, The Journal of comparative neurology.

[3]  Hong Zhang,et al.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors , 2008, Journal of Molecular Medicine.

[4]  F. Bermúdez-Silva,et al.  Presence of functional cannabinoid receptors in human endocrine pancreas , 2008, Diabetologia.

[5]  J. Aerssens,et al.  Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. , 2008, World journal of gastroenterology.

[6]  R. Palmiter,et al.  Multiple pathways involved in the biosynthesis of anandamide , 2008, Neuropharmacology.

[7]  K. Wright,et al.  Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation , 2008, British journal of pharmacology.

[8]  N. Ueda,et al.  Biosynthetic Pathways of the Endocannabinoid Anandamide , 2007, Chemistry & biodiversity.

[9]  S. Carding,et al.  Inflammatory bowel disease: cause and immunobiology , 2007, The Lancet.

[10]  V. Di Marzo,et al.  Endocannabinoid overactivity and intestinal inflammation , 2006, Gut.

[11]  B. Cravatt,et al.  Endocannabinoid Biosynthesis Proceeding through Glycerophospho-N-acyl Ethanolamine and a Role for α/β-Hydrolase 4 in This Pathway* , 2006, Journal of Biological Chemistry.

[12]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[13]  A. Saghatelian,et al.  Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. , 2006, Biochemistry.

[14]  M. Valenti,et al.  Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Davison,et al.  Review article: endocannabinoids and their receptors in the enteric nervous system , 2005, Alimentary pharmacology & therapeutics.

[16]  R. Capasso,et al.  Fatty acid amide hydrolase controls mouse intestinal motility in vivo. , 2005, Gastroenterology.

[17]  B. Lutz,et al.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract , 2005, Journal of Molecular Medicine.

[18]  S. Ward,et al.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. , 2005, Gastroenterology.

[19]  C. Fowler,et al.  The endocannabinoid signaling system: Pharmacological and therapeutic aspects , 2005, Pharmacology Biochemistry and Behavior.

[20]  Q. Pittman,et al.  Effects of cannabinoid receptor‐2 activation on accelerated gastrointestinal transit in lipopolysaccharide‐treated rats , 2004, British journal of pharmacology.

[21]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[22]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[23]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[24]  M. Parsons,et al.  Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. , 2003, European journal of pharmacology.

[25]  G. Gessa,et al.  Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. , 2003, European journal of pharmacology.

[26]  A. Izzo,et al.  Cannabinoids for gastrointestinal diseases: potential therapeutic applications , 2003, Expert opinion on investigational drugs.

[27]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Bisogno,et al.  Endocannabinoids as physiological regulators of colonic propulsion in mice. , 2002, Gastroenterology.

[29]  R. Capasso,et al.  Endocannabinoids and the gut. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[30]  A. Izzo,et al.  The gastrointestinal pharmacology of cannabinoids. , 2001, Current opinion in pharmacology.

[31]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[32]  R. Pertwee Cannabinoids and the gastrointestinal tract , 2001, Gut.

[33]  K. Waku,et al.  2-Arachidonoylglycerol and the cannabinoid receptors. , 2000, Chemistry and physics of lipids.

[34]  D. Piomelli,et al.  The endocannabinoid system as a target for therapeutic drugs. , 2000, Trends in pharmacological sciences.

[35]  S. Collins,et al.  Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis , 1998, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[36]  J. D. Richardson,et al.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors , 1998, Pain.

[37]  S. Yu,et al.  Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. , 1997, European journal of pharmacology.

[38]  B. Cravatt,et al.  Molecular characterization of human and mouse fatty acid amide hydrolases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[40]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[41]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[42]  H. Reimann,et al.  German Measles , 1956 .

[43]  D. Saur,et al.  Effect of cannabinoids on neural transmission in rat gastric fundus. , 2002, Canadian journal of physiology and pharmacology.

[44]  D. Piomelli,et al.  A role for the endogenous cannabinoid system in the peripheral control of pain initiation. , 2000, Progress in brain research.

[45]  Maxwell Wilson FINAL REPORT ON A THERAPEUTIC TRIAL , 1955 .